review Open AccessTop 1% cited
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Annals of Oncology · 2015 · Vol. 26(12) · pp. 2375–2391
Jarushka Naidoo✉(Johns Hopkins University)David B. Page(Providence Portland Medical Center)Bob T. Li(Memorial Sloan Kettering Cancer Center)Louise C. Connell(Memorial Sloan Kettering Cancer Center)Katja Schindler(Medical University of Vienna)Mario E. Lacouture(Memorial Sloan Kettering Cancer Center)Michael A. Postow(Cornell University)Jedd D. Wolchok(Cornell University)
Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchLung Cancer Treatments and MutationsMedicineImmune checkpointMelanomaPD-L1BlockadeNivolumabClinical trialImmunotherapyAdverse effectAntibody
MeSH terms
AnimalsAntibodies, MonoclonalExanthemaFatigueHumansNeoplasmsPneumoniaB7-H1 AntigenProgrammed Cell Death 1 Receptor
Citations
1,449
FWCI
62.22
field-weighted impact
References
119
Percentile
100%
vs. same field & year
Citations per year
Cited by
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Oncotarget · 2016 · 326 citations
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Frontiers in Pharmacology · 2017 · 618 citations
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Frontiers in Pharmacology · 2017 · 1,726 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 3,616 citations
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2017 · 2,321 citations
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
European Journal of Cancer · 2016 · 638 citations
References
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology · 2015 · 1,554 citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Cancer immunoediting: from immunosurveillance to tumor escape
Nature Immunology · 2002 · 5,232 citations
The blockade of immune checkpoints in cancer immunotherapy
Nature reviews. Cancer · 2012 · 13,550 citations
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity
Cancer Research · 2010 · 1,212 citations
Immunogenic death of colon cancer cells treated with oxaliplatin
Oncogene · 2009 · 1,118 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
New England Journal of Medicine · 2012 · 7,941 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.